WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform

WuXi XDC makes an ADC linker deal with Earendil for up to $885M

WuXi Biologics' antibody-drug conjugate spinout WuXi XDC said on Friday that it will be working with Earendil Labs to develop new antibody drug conjugates. AI-driven biologics developer Earendil will have access ...

WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform

SHANGHAI, Feb. 27, 2026 /PRNewswire/ — WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboration with Earendil Labs on WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology platform. Earendil Labs is an AI-powered biotech company focused on …

Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform

WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ — Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) on WuXi XDC’s proprietary WuXiTecan-2 payload-linker technology platform. WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufactur…